Article
T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia.
Oncotarget - 20 Oct 2015
Alachkar Houda, Mutonga Martin, Malnassy Gregory, Park Jae-Hyun, Fulton Noreen, Woods Alex, Meng Liping, Kline Justin, Raca Gordana, Odenike Olatoyosi, Takamatsu Naofumi, Miyamoto Takashi, Matsuo Yo, Stock Wendy, Nakamura Yusuke
Abstract excerpt
Gain-of-function mutations of FLT3 (FLT3-ITD), comprises up to 30% of normal karyotype acute myeloid leukemia (AML) and is associated with an adverse prognosis. Current FLT3 kinase inhibitors have been tested extensively, but have not yet resulted in a survival benefit and novel therapies are awaited. Here we show that T-LAK cell-originated protein kinase (TOPK), a mitotic kinase highly expressed in and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.